Background: Several pPivotal and post-marketing studies showed demonstrated the efficacy and
INTRODUCTION
Natalizumab is a monoclonal antibody directed against α4 subunit of integrin expressed on the surface of activated T-cells, preventing their transmigration through the blood-brain barrier (Chaudhuri et al, 2003) . Post-marketing studies have confirmed both short and long term persistence of natalizumab efficacy in Multiple Sclerosis (MS) patients (Oturai et al., 2009; Putzki et al., 2010) . However its profile is burdened with the risk of progressive multifocal leukoencephalopathy (PML), especially beyond 24 infusions (Clifford et.al, 2010) . Nowadays the combination of anamnestic information and the result of anti-JC virus antibodies test allows a better assessment of PML risk, towards a more individualized treatment approach. (Sorensen et al., 2012; Bloomgren et al., 2012) . For this reason, International Drug Agencies including FDA and EMEA recommended to re-evaluate natalizumab the bBenefit-Risk profile after two years of treatment in light of the increased risk of PML (puoi dare un link come referenza del documento emesso da queste agenize nel quale si precisa questo aspetto). On the other hand, the need to stop natalizumab treatment enlightened the risk of disease reactivation. A natalizumab phase II clinical trial already showed that the interruption of natalizumab treatment was associated to evidence of radiological and clinical activity (Miller et al., 2003) . Afterward, some post-marketing studies suggested that stopping natalizumab therapy was associated with a rebound of clinical and MRI activity beyond the expected disease reactivation level in a significant proportion of patients starting three months after the drug interruption (Killestein et al., 2010; Kerbrat er al., 2011; Vellinga et al., 2008; Havla et al., 2011) . Instead, some other studies showed a substantial return to pre-natalizumab disease activity (O'Connor et al., 2011; Stüve et al, 2009; Kaufman et al., 2011) . Nevertheless, the reliability of these observations has been questioned because the majority of these studies consisted of small case series and/or short term observations. The objective of this monocentric prospective study is to evaluate the effects of natalizumab discontinuation in a large cohort of patients with a follow-up of two years. The proportion of patients who presented clinical relapses and/or new or enlarging T2-weighted lesions and/or Gadolinium (Gd)-enhancing lesions was assessed. The effect of different alternative therapeutic options on the prevention of disease reactivation was also evaluated.
MATERIAL AND METHODS
We collected clinical and MRI data of 110 consecutive MS patients, followed as out patients at the San Raffaele MS Centre in Milan, who stopped natalizumab after at least one year of therapy. This study was planned within a post-marketing program of evaluatingaimed to evalutate the bBenefitrRisk profile of natalizumab NTZ treatment. Included patients underwent a mean of 24 ± 10.7 natalizumab courses (range: 12-57). Demographic and clinical data of patients are shown in Table   1 .
The mean follow-up after natalizumab discontinuation was 22.4 months (range: 6.3-37.8).
Reasons for drug discontinuation were: a) a shared decision with the treating neurologist due to anti-JC virus seropositivity combined with other risk factors (long treatment duration and/or previous use of immunosuppressive treatment) (n=94); b) self decision based on fear of PML (n=10) before the availability of anti-JC virus testing; c) pregnancy planning (n=6). Ten patients decided on their own to discontinue natalizumab before the availability of anti-JC virus testing for fear of PML. Ninety-four patients interrupted natalizumab after a shared doctor-patient choice because of anti-JC virus seropositivity combined with other risk factors (long treatment duration and/or previous use of immunosuppressive treatment). Additional 6 patients withdrawn therapy due to desire of pregnancy.
After stopping natalizumabNTZ stop, we proposed to all patients the to beginning shift to of an alternative therapy to all patients.. For patients who received natalizumab because of a breakthrough disease, the choice was based on a shared doctor-patient decision. Ninety patients (81.8%) started immunomodulant therapy, either glatiramer acetate (72 patients) or different formulations of beta-interferon-beta (18 patients) within approximately one month after last natalizumab infusion. The choice between these two first-line treatments was based on which treatment the patients did not respond to in the pre-natalizumab period. Ten (9.1%) additional patients who discontinued natalizumab started oral therapy with fingolimod after a mean of 4.6 months (range 3-6), such . This option was being available only sincesince April 2012. The remaining 10 patients (9.1%) did not start any disease modifying treatment (6 for desire of pregnancy planning and 4 for refusal of injective therapy before the availability of fingolimod availability). In order to prevent disease reactivationMoreover, 25 patients (22.7%) underwent monthly courses of intravenous (iv) methylprednisolone (1 g for 2 days of 1 gram of ) intravenous (i.v.) methylprednisolone starting 2 months after natalizumab discontinuation in addition to disease modifying therapies.
Neurological examinations were performed every three months, or in case of exacerbation. Most pPatients underwent brain MRI scans approximately at the 3rd (± 1), 6th (± 1) and 12th month (+3) after natalizumab interruption. Additional MRI scans were sometime have been performed in case of if a relapse occurrenced. One hundred patients (91.1%) underwent the 3rd month brain MRI and 80 (72.7%) the 6th month scan; all patients had at least one MRI in the first six months after natalizumab NTZ discontinuation. Moreover, 74 patients (67.2%) had a brain MRI at one year after discontinuationdrug stop. We considered defined new or enlarging T2-weighted lesions and/or Gadolinium (Gd)-enhancing lesions as active scans those with new or enlarging T2-weighted lesions and/or Gadolinium (Gd)-enhancing lesions. Patients were classified as "disease activity free" if the absence of relapses was combined with the absence of active scans and disease progression. Disease progression was defined as an increase of Expanded Disability Status Scale (EDSS) of 1.0 point on the Expanded Disability Status Scale (EDSS) for patients with baseline EDSS < or = 5.5 and of 0.5 point for baseline EDSS > or = 6.0. Patients were classified as "disease activity free" if the absence of relapses was combined with the absence of active scans and disease progression.
Based on the pre-natalizumab radiological and clinical features of the disease activity before NTZ start, we divided our cohort of patients in two subgroups, named "highly active" and "lowly active".
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We classified our patients as "highly active" if they presented an annualized relapse rate (ARR) ≥ 3 in the year prior to natalizumab and/or ≥ 4 gadolinium-enhancing lesions at baseline brain MRI.
The remaining patients were defined as "lowly active".
We also tried to identify patients who presented the conventionally called "rebound activity", during in which the severity of relapses and/or the number of new T2 or Gd-enhancing lesions was much higher than the pre-natalizumab activity. Literature lacks of a clear and univocal definition of "rebound activity", therefore we opted decided to perform a for a case by case review case by case of disease activity by MS-expert neurologists (metti le iniziali fra parentesi). We arbitrarily decided to classify patients as rebound activity having Selected patients presented at least one of the following features: a) a clinically significant increase of relapse rate in comparison to prenatalizumab disease course (cosa intendi?); b) one or more severe relapses with sustained disability progression; c) 5 or more new large T2 lesions and/or at least 10 more Gd-enhancing lesions than pre-natalizumab baseline scan.
T-test was used to compare parametric variables and Mann-Whitney test for non-parametric valuesones. Kaplan-Meier curves were built to evaluate the proportion of patients free from relapses, MRI activity or combined disease activity at different time-points. We compared survival curves by performing the log-rank (Mantel-Cox) test.
Local Ethical Committee approval was obtained before data collection.
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RESULTS
The proportion of patients who was relapse free during the follow up was 83% at 3rd month, 60% at 6th month and 44% at one year ( figure 1 a) . Half of the patients presented a relapse within 10 months after last natalizumab infusion (median survival time of 9.77 months). The ARR in the first year after natalizumab NTZ discontinuation significantly increased to 0.84 compared to 0.06 observed on during the NTZ treatment (p<0.0001).
The risk of rRelapse frequencys in the entire population had a peaked at in the 4th month, remained high until the 98th month and then returned to a level similar to the one observed during natalizumab treatment declined at the end of the first year after discontinuation to a value close to that observed during natalizumab treatment (figure 2).
Similarly, aAt one-year follow-up the mean median Expanded Disability Status Scale (EDSS) significantly increased from xx to 3.0 (p<0.001). Specifically , and 16 patients (14.5% of the total), who had a baseline EDSS >3.0 at the time of NTZ discontinuation,.experienced aas a result of relapses a sustained progression was observed in 16 patients (14.5% of the whole cohort), especially in the subgroup of patients with a baseline EDSS equal or greater than 3.0. of disability after NTZ stop.
The proportion of patients "free from MRI activity" was 85% at 3rd month 3, 54% at 6th month 6 and 35% at one year ( figure 1 b) . The mean number of Gd-enhancing lesions increased from 1.46 at the 3rd month 3 to 3.07 at the 6th month 6 and then declined to 1.700 at one year, compared to xx during NTZ treatment.
The proportion of "disease-activity free" patients was 75% at 3rd month 3, 42% at 6th month 6 and 25% at one year ( figure 1 c) . The risk of disease reactivation was higher between the second and the eighth month after natalizumab suspension. Toglierei la frase in rosso: è già stata detta piu' volte.
Beyond this time-point the slop reducedAfter 1-year of follow-up, the proportion of disease activity Patients who received an alternative disease modifying therapy after natalizumab discontinuation had a significantly higher probability to remain "disease-activity free" compared to untreated patients (30% versus 0% at 1-one year f-up after NTZ discontinuation). On the contrary, the type of treatmentdrug , whether immunomodulants like IFN or GA (IM) or fingolimod (FTY), had no effects impact on the condition proportion of disease activity free patients (p=) (figure 3). In particular, a disease reactivation was observed in 6 out of the /10 patients who started fingolimod treatment and in xx/xx who began immunomodulant ones (p=). Moreover, we did not find any evidence of disease activity reduction in tThe 25 patients who received preventive steroid courses monthly i.v. methylprednisolone cycles after NTZ treatment compared to those who did not receive them (p=)did not show a significant lower level of MS activity if compared to patients who did not receive preventive steroid courses.
Twenty-five (34%) of 73 patients showing disease reactivation during immunomodulante treatmentsunder IM therapy in the first year after NTZ stop shifted to second-line therapies within 3 months after relapse and/or active MRI occurrence. Specifically 16 returned to natalizumab and 9 started other alternative second-line therapies (i.e. fingolimod, nN=7;, or i.v. immunosuppression with pulsed cyclophosphamide immunosuppression,, Nn=2). We compared these two groups of patients with 48 patients who did not change disease modifying therapy. At a mean follow-up of 17 months we found a significant lower risk of persistentreduction of frequency of disease activity in the those who returned to natalizumab groupNTZ (p< 0,05), while there was no apparent advantage in shifting to other second-line therapies (p=ns), even if data were inflated by a small sample size.; these data are probably affected by the small number of patients included in this analysis. Overall the risk of disease reactivation after NTZ stop was statistically correlatedincreased in patients both with a higher ARR in the last year before starting natalizumabNTZ start (2.08 in reactivated patients versus 1.54 in stable patientsones;, p<0.005) and in those with a higher mean number of enhancing lesions in the pre-treatment brain MRI (2.60 versus 1.08;, p<0.03704). Moreover, patients defined as "highly active" in the year prior to natalizumab (ARR ≥ 3 and/ or ≥ 4 gadolinium-enhancing lesions at baseline brain MRI) had a higher risk of disease reactivation (xx vs xxx; p=0.004); (figure 4).
Finally we compared clinical and radiological disease activity in the period after NTZ stop with the one in the reactivation after discontinuation to disease activity in the year before starting natalizumab. Post-natalizumab NTZ ARR was significantly lower than pre-natalizumab ARRNTZ one (1.98 versus 0.84;, p<0.05). However it is interesting to note that the mean number of Gdenhancing lesions at the 6th month after discontinuation was significantly higher than the number observed at the beginning of natalizumab treatment (3.07 versus 2.24;, p<0.001).
Moreover we identified 11 patients (10%) who presented the conventionally called rebound activity in which the severity of relapses and/or the number of new T2 or Gd-enhancing lesions was much higher than pre-natalizumab activity. Specifically, 4 patients had both either clinical and neuroradiological severe reactivation, whereas 5 patients showed only a remarkable MRI rebound activity, and remaining . The last two patients experienced had a very disabling relapse with only a few enhancing lesions probably because MRI scan was performed after i.v. steroid therapy.
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DISCUSSION
Since natalizumab safety profile forces demands to cautiouslya cautious evaluation of itse long-term treatmentuse, concerns on disease reactivation after natalizumab suspension were addressed in many reports. Altogether available data confirm that disease stability, reached during natalizumab therapy, does not continue after treatment discontinuation, since the drug does not cause long-term immunological changes.
Our study is the result of everyday clinical practice and wasa real world study conducted in one of the largest monocentric cohort of MS patients stopping natalizumab with a 1-year follow-up,.
Moreover patients were followed for more than a year thus providing long term data on disease course after withdrawal from natalizumab withdrawal. These strengths could at least partially compensate the expected bias of every nonrandomised study conducted in the clinical setting. Till now, a part from many several observational studies with smaller cohorts than ours (references?), there is only one ongoing clinical trial (RESTORE) which that compares patients continuing natalizumab with patients those receiving using placebo or an alternative treatment (glatiramer acetateGA, beta-interferonIFN-beta or IV iv steroids according to neurologists' choice). Preliminary data of this trial showed a proportion of disease reactivation of about 50% seven months after withdrawal from natalizumab, with no significant differences between either in the placebo or inand the alternative treatment group arm (Kaufman et al., 2012) .
Our data showIn this papr we show that only a quarter 25% of our patients remained "diseaseactivity free" one year after discontinuation. As It is known in from the literature that the concentration of, natalizumab concentrationNTZ progressively decrease within 3 months, whereas changes induced on the immune system could be detected until 6 months after discontinuation (Stüve et al, 2006 ). Accordingly we found a peak of the risk of relapse risk in the at the 4th th month after discontinuation, and thisthe risk is stillbeing high untilat the 8th month 8 and decreasing at 1-year follow-upwhile after one year it returns to a lower value. Similarly we have the maximum number ofalso gGd-enhancing lesions at MRI scans performed were more frequent at the 6th month period after NTZ suspensionstop, being. The mean number of enhancing lesions at this time point is significantly higher even if compared to brain scans performedthan in the period before the beginning of natalizumab therapyNTZ start. Our study confirmed literature data since the majority of our patients showed a substantial return to their pre-natalizumab disease activity (references?). However according to clinical and radiological data only 10% of our cohort presented the so-called rebound activity. Interestingly disease reactivation was observed mostly during a "high risk period" between the second and the eighth month after drug discontinuation. Then, after this period, we observed a reduction in the slop of the survival curve of disease activity, as well as a decline of relapse risk and of the mean number of Gd-enhancing lesions ( figure 1 and 3 ).
Higher ARR and mean higher enhancing lesions in the year before natalizumab were identified as predictive factors associated to an increased risk of disease recurrence. Likewise O'Connor found that patients enrolled inof registrative registered trials with a higher level of prior-to-natalizumab disease activity tended to have a higher ARR after discontinuation (O'Connor et al., 2011) .
Our study was also aimed to evaluate the effects of starting an alternative treatment soon after natalizumab interruption. According to our analysis, first-line immunomodulants can reduce the degree of reactivation after natalizumab discontinuation only in a subgroup of patientshowever they fail to prevent it in most of the patients. These findings are consistent with data published by O'Connor (O'Connor et al., 2011) and Cohen (Cohen M et al., 2013) who observed a return of MS activity regardless the beginning of preventive therapy after natalizumab suspensionstop. Moreover we did not observe a statistically significant effect of doses of i.v. methylprednisoloneintravenous steroid cycles in preventing MS reactivation as reported in another survey (Borriello et al., 2012) .
Considering that seventy-five percent of our cohort showed signs of disease reactivation after NTZ discontinuation, patients should be closely monitored to detect clinical and/or radiological disease activity as soon as possible in order to readily change preventive therapy or, even going backto return to natalizumab therapy despite PML risk. A strict clinical observation is even more important for patients with residual disability after relapse occurrenceconsidering that relapses might result in a sustained progression.
Moreover, given that a higher pre-natalizumab disease activity seems to be a factor predicting reactivation, a careful evaluation of single-patient bBenefit-rRisk ratio is mandatory when stopping natalizumab. Patients at risk of developing PML have also toshould be stratified according to MS their own disease history, i.e. clinical characteristics before starting natalizumabNTZ start, as well as and to residual therapeutic options and , as well as possible contraindications to other therapies.
Due to delays in the authorization of fingolimod approval in Italy, only a very small proportion of our patients started the an oral drug after natalizumab discontinuation, therefore we cannot give indication on its efficacy in preventing reactivation. The lack of difference of efficacy between fingolimod and apparent similarity of behavior with immunomodulants as shift therapy that we observed in our study could be just a statistical bias due toartifact determined by the small sample size. Therefore, mMore data are needed to determine if fingolimod could be a feasible therapeutic option just after natalizumab, even if it is worthwhile to mention that first reports in literature show disease reactivation was detected in half of the patients shifting to oral therapy by an Italian group (Rinaldi et al., 2012) . More rRecently, in a cohort of MS patients recruited for a safety study, those who started fingolimod after natalizumab discontinuation showed a low risk of relapses (aggiungi I numeri). Nevertheless this risk is was 3-fold higher in patients starting fingolimod 3-6 months after natalizumab compared with to naive patients who never received natalizumab (Comi et al., 2013) .
CONCLUSIONS
In our cohortthis cross-sectional study, 3 out of 4 patients presented disease reactivation despite the starting beginning of an alternative treatment after natalizumab discontinuation. This observation suggests that at least between the second and the eighth month after the last dose, the so called "high risk period", neitheror immunomodulants nor fingolimod provide an adequate protection from disease reactivation. This phase, though transient, could be potentially dangerous, since 14.5% of our patients showed sustained progression as a result of relapses; therefore, we need to develop better more effective strategies to deal with such athis challenge. Frequent Serial MRI evaluations in the first 6-8 months after discontinuation mightay help to detect patients with strong disease reactivation. In these patients, a more aggressive approach, such as an immunosuppressive treatment with i.v. pulsed cyclophosphamide, could be attempted. Finally in patients with lower risk of PML the opportunity to restart natalizumab should also be considered in combination with close clinical and MRI monitoring. . Survival curves analysis of disease activity-free patients free from disease activity after natalizumab NTZ discontinuation comparing a group of pre-natalizumab "highly active" patients (HA; continuous line) and a group of pre-natalizumab "lowly active" patients (LA; dashed line).
The x axis shows the months after natalizumab discontinuation.
The p value refers to the log-rank test.
Difference observed is statistically significant (p=0.004). X Axis shows months after natalizumab discontinuation.
